Dolutegravir/Lamivudine/Tenofovir

多替拉韦/拉米夫定/替诺福韦

Report date: 2026/02/28 09:28:56

Base Information

Drug NameDolutegravir/Lamivudine/Tenofovir
Drug Alias Name多替拉韦拉米夫定替诺福韦
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHIV integrase inhibitorsReverse transcriptase inhibitors
TargetsHIV integraseReverse transcriptase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsYes
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesShanghai Desano Bio-Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Desano Bio-Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A